0

Close
 
Upcoming Allied Market Research
2023
Cancer Patient Registry Software Market

Cancer Patient Registry Software Market

by Type (Standalone Software, Integrated Software), by Deployment Model (On-premise, Cloud-based), by Functionality (Cancer Reporting to Meet State and Federal Regulations, Patient Care Management, Product Outcome Evaluation, Medical Research and Clinical Studies), by Database (Commercial Databases, Public Databases) and by End User (Government Organizations andThird-party Administrators (TPAS), Hospitals and Medical Practices, Pharmaceutical, Biotechnology, and Medical Device Companies, Private Payers, Research Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Healthcare IT
Report Code: A10261
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cancer Patient Registry Software Market

Request Now !

Cancer Patient Registry Software Market Outlook – 2027

Cancer patient registry software is a computerized database that is used for the organization, collection, and storing of the data of all the cancer patients for the evaluation of cancer-specific results, drug or medical device exposure, and conditions.

Cancer Patient Registry Software Market

Cancer Registry Software’s are kind of a disease registry that is used to maintain and also add a new cancer incidence reporting system. The cancer registry systems are often used as a resource where information is stored for cancer investigation and the possible causes of cancer.

These registries are very important as cancer is the most leading cause for the deaths and this collection of data on cancer cases helps right from the diagnosis to the survivorship which helps in identifying the trends to identify and help in improving patients' care and fighting against cancer.

COVID-19 scenario analysis:

With the outbreak of COVID-19 globally and the stipulated lockout, there is an ongoing downturn in the healthcare market. Aside from communities, COVID-19 was equally disastrous for major world economies, especially the healthcare sector. Prominent stakeholders are continuing to adapt their strategy to the rapidly changing situation. COVID-19 is projected to have significant long-term impacts on the healthcare industry. Countries and major players would have to undertake critical healthcare changes until the crisis takes a back seat.

Technological progress, cost containment, and increased access will in the near future be an integral part of healthcare reforms. Digital health and telehealth have taken a front seat in the ongoing outbreak. COVID-19 re-emphasized the importance of remote diagnosis, care, and consultation. Over the past few years, regulatory and behavioral barriers have slowed Telehealth growth. However, since many healthcare providers are currently working on video conferencing and telephone calls, this segment's growth will increase several folds over the next two years. The social distancing measures also mandated online consultation of patients with moderate symptoms. In addition, it greatly reduces the burden on hospitals already swamped by counts of COVID-19 patients. Medical IoT devices that live at home with patients are now being used for optimizing outpatient treatment and minimizing repeat visits, and these devices can be further used in a crisis situation. The pandemic led to severe resource constraints. This is expected to result in the development of competitive pricing and value-based pricing models, which will accelerate the market growth in the future.

Owing to such factors, COVID 19 is expected to have a significant impact on the Cancer Patient Registry Software market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

An increase in the frequency of cancer has been observed, government initiatives benefiting the users, growing pressure for the betterment of the patient care and reduction in the costs of healthcare, the adoption rate of HER increasing substantially, and increasing cancer patient registry software are the major factors propelling the growth of the cancer patient registry software market.

Governments of various countries are also focusing on awareness about cancer and health management of the population; healthcare costs coming down and coordinated care are some of the other factors affecting the growth of the cancer patient registry software market.

High pressure on the healthcare facilities of cancer, increasing funding by the government through initiatives for the encouragement of the cancer registries, healthcare IT sector has also been making high investments are also some of the other factors affecting the cancer patient registry software market positively.

Integration of registries of all the hospitals at one point-of-care, hospitals are participating in observational studies and utilize one data capture system to change their workflow for the accommodation of non-harmonized research demands.

New product launches and acquisitions to flourish the market:

On November 5th, 2018, Onco made advancements in their OncoLog Version 4.4.0 which includes the newest requirements asked by the NAACCR, AJCC, CoC, and SEER.

On January 31st, 2018, Elekta and IBM Watson Health collaborated to incorporate Watson for Oncology with Elekta’s cancer care solutions.

Surge in usage in research centers applications:

Research centers utilize the cancer patient registry software for tracking the patients' health and their eligibility for clinical trials. Researchers utilize this data for the development of new products as well. Some research centers maintain their records of the patients, and have segmented based on the cancer type they are suffering from. Apart from this, various research centers are also keeping up with the upgrades in cancer patient registry software with the help of healthcare associations and centers.

Key benefits of the report:

  • This study presents the analytical depiction of the global Cancer Patient Registry Software industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Cancer Patient Registry Software market share.
  • The current market is quantitatively analyzed to highlight the global market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global Cancer Patient Registry Software market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Cancer Patient Registry Software Market research report:

  • What are the leading market players active in the Cancer Patient Registry Software market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

     Cancer Patient Registry Software Market Report Highlights

    Aspects Details
    By Type
    • Standalone Software
    • Integrated Software
    By Deployment Model
    • On-premise
    • Cloud-based
    By Functionality
    • Cancer Reporting to Meet State and Federal Regulations
    • Patient Care Management
    • Product Outcome Evaluation
    • Medical Research and Clinical Studies
    By Database
    • Commercial Databases
    • Public Databases
    By End User
    • Government Organizations andThird-party Administrators (TPAS)
    • Hospitals and Medical Practices
    • Pharmaceutical, Biotechnology, and Medical Device Companies
    • Private Payers
    • Research Centers
    By Region
    • North America  (U.S., Canada, Mexico)
    • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
    • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
    • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
    Key Market Players Elekta, Electronic Registry Systems, Inc., Conduent Inc, IBM, Onco, Inc., C/Net Solutions, Rocky Mountain Cancer Data Systems, Ordinal Data Inc., HimagineSolutions Inc., McKesson Corporation
     

    • CHAPTER 1: INTRODUCTION

      • 1.1. Report Description

      • 1.2. Key Market Segments

      • 1.3. Key Benefits

      • 1.4. Research Methodology

        • 1.4.1. Primary Research

        • 1.4.2. Secondary Research

        • 1.4.3. Analyst Tools and Models

    • CHAPTER 2: EXECUTIVE SUMMARY

      • 2.1. CXO Perspective

    • CHAPTER 3: MARKET LANDSCAPE

      • 3.1. Market Definition and Scope

      • 3.2. Key Findings

        • 3.2.1. Top Investment Pockets

        • 3.2.2. Top Winning Strategies

      • 3.3. Porter's Five Forces Analysis

        • 3.3.1. Bargaining Power of Suppliers

        • 3.3.2. Threat of New Entrants

        • 3.3.3. Threat of Substitutes

        • 3.3.4. Competitive Rivalry

        • 3.3.5. Bargaining Power among Buyers

      • 3.5. Market Dynamics

        • 3.5.1. Drivers

        • 3.5.2. Restraints

        • 3.5.3. Opportunities

      • 3.6. COVID-19 Impact Analysis

    • CHAPTER 4: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE

      • 4.1. Market Overview

        • 4.1.1 Market Size and Forecast, By Type

      • 4.2. Standalone Software

        • 4.2.1. Key Market Trends, Growth Factors and Opportunities

        • 4.2.2. Market Size and Forecast, By Region

        • 4.2.3. Market Share Analysis, By Country

      • 4.3. Integrated Software

        • 4.3.1. Key Market Trends, Growth Factors and Opportunities

        • 4.3.2. Market Size and Forecast, By Region

        • 4.3.3. Market Share Analysis, By Country

    • CHAPTER 5: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL

      • 5.1. Market Overview

        • 5.1.1 Market Size and Forecast, By Deployment Model

      • 5.2. On-premise

        • 5.2.1. Key Market Trends, Growth Factors and Opportunities

        • 5.2.2. Market Size and Forecast, By Region

        • 5.2.3. Market Share Analysis, By Country

      • 5.3. Cloud-based

        • 5.3.1. Key Market Trends, Growth Factors and Opportunities

        • 5.3.2. Market Size and Forecast, By Region

        • 5.3.3. Market Share Analysis, By Country

    • CHAPTER 6: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY

      • 6.1. Market Overview

        • 6.1.1 Market Size and Forecast, By Functionality

      • 6.2. Cancer Reporting To Meet State And Federal Regulations

        • 6.2.1. Key Market Trends, Growth Factors and Opportunities

        • 6.2.2. Market Size and Forecast, By Region

        • 6.2.3. Market Share Analysis, By Country

      • 6.3. Patient Care Management

        • 6.3.1. Key Market Trends, Growth Factors and Opportunities

        • 6.3.2. Market Size and Forecast, By Region

        • 6.3.3. Market Share Analysis, By Country

      • 6.4. Product Outcome Evaluation

        • 6.4.1. Key Market Trends, Growth Factors and Opportunities

        • 6.4.2. Market Size and Forecast, By Region

        • 6.4.3. Market Share Analysis, By Country

      • 6.5. Medical Research And Clinical Studies

        • 6.5.1. Key Market Trends, Growth Factors and Opportunities

        • 6.5.2. Market Size and Forecast, By Region

        • 6.5.3. Market Share Analysis, By Country

    • CHAPTER 7: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE

      • 7.1. Market Overview

        • 7.1.1 Market Size and Forecast, By Database

      • 7.2. Commercial Databases

        • 7.2.1. Key Market Trends, Growth Factors and Opportunities

        • 7.2.2. Market Size and Forecast, By Region

        • 7.2.3. Market Share Analysis, By Country

      • 7.3. Public Databases

        • 7.3.1. Key Market Trends, Growth Factors and Opportunities

        • 7.3.2. Market Size and Forecast, By Region

        • 7.3.3. Market Share Analysis, By Country

    • CHAPTER 8: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER

      • 8.1. Market Overview

        • 8.1.1 Market Size and Forecast, By End User

      • 8.2. Government Organizations AndThird-party Administrators (TPAS)

        • 8.2.1. Key Market Trends, Growth Factors and Opportunities

        • 8.2.2. Market Size and Forecast, By Region

        • 8.2.3. Market Share Analysis, By Country

      • 8.3. Hospitals And Medical Practices

        • 8.3.1. Key Market Trends, Growth Factors and Opportunities

        • 8.3.2. Market Size and Forecast, By Region

        • 8.3.3. Market Share Analysis, By Country

      • 8.4. Pharmaceutical, Biotechnology, And Medical Device Companies

        • 8.4.1. Key Market Trends, Growth Factors and Opportunities

        • 8.4.2. Market Size and Forecast, By Region

        • 8.4.3. Market Share Analysis, By Country

      • 8.5. Private Payers

        • 8.5.1. Key Market Trends, Growth Factors and Opportunities

        • 8.5.2. Market Size and Forecast, By Region

        • 8.5.3. Market Share Analysis, By Country

      • 8.6. Research Centers

        • 8.6.1. Key Market Trends, Growth Factors and Opportunities

        • 8.6.2. Market Size and Forecast, By Region

        • 8.6.3. Market Share Analysis, By Country

    • CHAPTER 9: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION

      • 9.1. Market Overview

        • 9.1.1 Market Size and Forecast, By Region

      • 9.2. North America

        • 9.2.1. Key Market Trends and Opportunities

        • 9.2.2. Market Size and Forecast, By Type

        • 9.2.3. Market Size and Forecast, By Deployment Model

        • 9.2.4. Market Size and Forecast, By Functionality

        • 9.2.5. Market Size and Forecast, By Database

        • 9.2.6. Market Size and Forecast, By End User

        • 9.2.7. Market Size and Forecast, By Country

        • 9.2.8. U.S. Cancer Patient Registry Software Market

          • 9.2.8.1. Market Size and Forecast, By Type
          • 9.2.8.2. Market Size and Forecast, By Deployment Model
          • 9.2.8.3. Market Size and Forecast, By Functionality
          • 9.2.8.4. Market Size and Forecast, By Database
          • 9.2.8.5. Market Size and Forecast, By End User

        • 9.2.9. Canada Cancer Patient Registry Software Market

          • 9.2.9.1. Market Size and Forecast, By Type
          • 9.2.9.2. Market Size and Forecast, By Deployment Model
          • 9.2.9.3. Market Size and Forecast, By Functionality
          • 9.2.9.4. Market Size and Forecast, By Database
          • 9.2.9.5. Market Size and Forecast, By End User

        • 9.2.10. Mexico Cancer Patient Registry Software Market

          • 9.2.10.1. Market Size and Forecast, By Type
          • 9.2.10.2. Market Size and Forecast, By Deployment Model
          • 9.2.10.3. Market Size and Forecast, By Functionality
          • 9.2.10.4. Market Size and Forecast, By Database
          • 9.2.10.5. Market Size and Forecast, By End User

      • 9.3. Europe

        • 9.3.1. Key Market Trends and Opportunities

        • 9.3.2. Market Size and Forecast, By Type

        • 9.3.3. Market Size and Forecast, By Deployment Model

        • 9.3.4. Market Size and Forecast, By Functionality

        • 9.3.5. Market Size and Forecast, By Database

        • 9.3.6. Market Size and Forecast, By End User

        • 9.3.7. Market Size and Forecast, By Country

        • 9.3.8. France Cancer Patient Registry Software Market

          • 9.3.8.1. Market Size and Forecast, By Type
          • 9.3.8.2. Market Size and Forecast, By Deployment Model
          • 9.3.8.3. Market Size and Forecast, By Functionality
          • 9.3.8.4. Market Size and Forecast, By Database
          • 9.3.8.5. Market Size and Forecast, By End User

        • 9.3.9. Germany Cancer Patient Registry Software Market

          • 9.3.9.1. Market Size and Forecast, By Type
          • 9.3.9.2. Market Size and Forecast, By Deployment Model
          • 9.3.9.3. Market Size and Forecast, By Functionality
          • 9.3.9.4. Market Size and Forecast, By Database
          • 9.3.9.5. Market Size and Forecast, By End User

        • 9.3.10. Italy Cancer Patient Registry Software Market

          • 9.3.10.1. Market Size and Forecast, By Type
          • 9.3.10.2. Market Size and Forecast, By Deployment Model
          • 9.3.10.3. Market Size and Forecast, By Functionality
          • 9.3.10.4. Market Size and Forecast, By Database
          • 9.3.10.5. Market Size and Forecast, By End User

        • 9.3.11. Spain Cancer Patient Registry Software Market

          • 9.3.11.1. Market Size and Forecast, By Type
          • 9.3.11.2. Market Size and Forecast, By Deployment Model
          • 9.3.11.3. Market Size and Forecast, By Functionality
          • 9.3.11.4. Market Size and Forecast, By Database
          • 9.3.11.5. Market Size and Forecast, By End User

        • 9.3.12. UK Cancer Patient Registry Software Market

          • 9.3.12.1. Market Size and Forecast, By Type
          • 9.3.12.2. Market Size and Forecast, By Deployment Model
          • 9.3.12.3. Market Size and Forecast, By Functionality
          • 9.3.12.4. Market Size and Forecast, By Database
          • 9.3.12.5. Market Size and Forecast, By End User

        • 9.3.13. Russia Cancer Patient Registry Software Market

          • 9.3.13.1. Market Size and Forecast, By Type
          • 9.3.13.2. Market Size and Forecast, By Deployment Model
          • 9.3.13.3. Market Size and Forecast, By Functionality
          • 9.3.13.4. Market Size and Forecast, By Database
          • 9.3.13.5. Market Size and Forecast, By End User

        • 9.3.14. Rest Of Europe Cancer Patient Registry Software Market

          • 9.3.14.1. Market Size and Forecast, By Type
          • 9.3.14.2. Market Size and Forecast, By Deployment Model
          • 9.3.14.3. Market Size and Forecast, By Functionality
          • 9.3.14.4. Market Size and Forecast, By Database
          • 9.3.14.5. Market Size and Forecast, By End User

      • 9.4. Asia-Pacific

        • 9.4.1. Key Market Trends and Opportunities

        • 9.4.2. Market Size and Forecast, By Type

        • 9.4.3. Market Size and Forecast, By Deployment Model

        • 9.4.4. Market Size and Forecast, By Functionality

        • 9.4.5. Market Size and Forecast, By Database

        • 9.4.6. Market Size and Forecast, By End User

        • 9.4.7. Market Size and Forecast, By Country

        • 9.4.8. China Cancer Patient Registry Software Market

          • 9.4.8.1. Market Size and Forecast, By Type
          • 9.4.8.2. Market Size and Forecast, By Deployment Model
          • 9.4.8.3. Market Size and Forecast, By Functionality
          • 9.4.8.4. Market Size and Forecast, By Database
          • 9.4.8.5. Market Size and Forecast, By End User

        • 9.4.9. Japan Cancer Patient Registry Software Market

          • 9.4.9.1. Market Size and Forecast, By Type
          • 9.4.9.2. Market Size and Forecast, By Deployment Model
          • 9.4.9.3. Market Size and Forecast, By Functionality
          • 9.4.9.4. Market Size and Forecast, By Database
          • 9.4.9.5. Market Size and Forecast, By End User

        • 9.4.10. India Cancer Patient Registry Software Market

          • 9.4.10.1. Market Size and Forecast, By Type
          • 9.4.10.2. Market Size and Forecast, By Deployment Model
          • 9.4.10.3. Market Size and Forecast, By Functionality
          • 9.4.10.4. Market Size and Forecast, By Database
          • 9.4.10.5. Market Size and Forecast, By End User

        • 9.4.11. South Korea Cancer Patient Registry Software Market

          • 9.4.11.1. Market Size and Forecast, By Type
          • 9.4.11.2. Market Size and Forecast, By Deployment Model
          • 9.4.11.3. Market Size and Forecast, By Functionality
          • 9.4.11.4. Market Size and Forecast, By Database
          • 9.4.11.5. Market Size and Forecast, By End User

        • 9.4.12. Australia Cancer Patient Registry Software Market

          • 9.4.12.1. Market Size and Forecast, By Type
          • 9.4.12.2. Market Size and Forecast, By Deployment Model
          • 9.4.12.3. Market Size and Forecast, By Functionality
          • 9.4.12.4. Market Size and Forecast, By Database
          • 9.4.12.5. Market Size and Forecast, By End User

        • 9.4.13. Thailand Cancer Patient Registry Software Market

          • 9.4.13.1. Market Size and Forecast, By Type
          • 9.4.13.2. Market Size and Forecast, By Deployment Model
          • 9.4.13.3. Market Size and Forecast, By Functionality
          • 9.4.13.4. Market Size and Forecast, By Database
          • 9.4.13.5. Market Size and Forecast, By End User

        • 9.4.14. Malaysia Cancer Patient Registry Software Market

          • 9.4.14.1. Market Size and Forecast, By Type
          • 9.4.14.2. Market Size and Forecast, By Deployment Model
          • 9.4.14.3. Market Size and Forecast, By Functionality
          • 9.4.14.4. Market Size and Forecast, By Database
          • 9.4.14.5. Market Size and Forecast, By End User

        • 9.4.15. Indonesia Cancer Patient Registry Software Market

          • 9.4.15.1. Market Size and Forecast, By Type
          • 9.4.15.2. Market Size and Forecast, By Deployment Model
          • 9.4.15.3. Market Size and Forecast, By Functionality
          • 9.4.15.4. Market Size and Forecast, By Database
          • 9.4.15.5. Market Size and Forecast, By End User

        • 9.4.16. Rest of Asia Pacific Cancer Patient Registry Software Market

          • 9.4.16.1. Market Size and Forecast, By Type
          • 9.4.16.2. Market Size and Forecast, By Deployment Model
          • 9.4.16.3. Market Size and Forecast, By Functionality
          • 9.4.16.4. Market Size and Forecast, By Database
          • 9.4.16.5. Market Size and Forecast, By End User

      • 9.5. LAMEA

        • 9.5.1. Key Market Trends and Opportunities

        • 9.5.2. Market Size and Forecast, By Type

        • 9.5.3. Market Size and Forecast, By Deployment Model

        • 9.5.4. Market Size and Forecast, By Functionality

        • 9.5.5. Market Size and Forecast, By Database

        • 9.5.6. Market Size and Forecast, By End User

        • 9.5.7. Market Size and Forecast, By Country

        • 9.5.8. Brazil Cancer Patient Registry Software Market

          • 9.5.8.1. Market Size and Forecast, By Type
          • 9.5.8.2. Market Size and Forecast, By Deployment Model
          • 9.5.8.3. Market Size and Forecast, By Functionality
          • 9.5.8.4. Market Size and Forecast, By Database
          • 9.5.8.5. Market Size and Forecast, By End User

        • 9.5.9. South Africa Cancer Patient Registry Software Market

          • 9.5.9.1. Market Size and Forecast, By Type
          • 9.5.9.2. Market Size and Forecast, By Deployment Model
          • 9.5.9.3. Market Size and Forecast, By Functionality
          • 9.5.9.4. Market Size and Forecast, By Database
          • 9.5.9.5. Market Size and Forecast, By End User

        • 9.5.10. Saudi Arabia Cancer Patient Registry Software Market

          • 9.5.10.1. Market Size and Forecast, By Type
          • 9.5.10.2. Market Size and Forecast, By Deployment Model
          • 9.5.10.3. Market Size and Forecast, By Functionality
          • 9.5.10.4. Market Size and Forecast, By Database
          • 9.5.10.5. Market Size and Forecast, By End User

        • 9.5.11. UAE Cancer Patient Registry Software Market

          • 9.5.11.1. Market Size and Forecast, By Type
          • 9.5.11.2. Market Size and Forecast, By Deployment Model
          • 9.5.11.3. Market Size and Forecast, By Functionality
          • 9.5.11.4. Market Size and Forecast, By Database
          • 9.5.11.5. Market Size and Forecast, By End User

        • 9.5.12. Argentina Cancer Patient Registry Software Market

          • 9.5.12.1. Market Size and Forecast, By Type
          • 9.5.12.2. Market Size and Forecast, By Deployment Model
          • 9.5.12.3. Market Size and Forecast, By Functionality
          • 9.5.12.4. Market Size and Forecast, By Database
          • 9.5.12.5. Market Size and Forecast, By End User

        • 9.5.13. Rest of LAMEA Cancer Patient Registry Software Market

          • 9.5.13.1. Market Size and Forecast, By Type
          • 9.5.13.2. Market Size and Forecast, By Deployment Model
          • 9.5.13.3. Market Size and Forecast, By Functionality
          • 9.5.13.4. Market Size and Forecast, By Database
          • 9.5.13.5. Market Size and Forecast, By End User

    • CHAPTER 10: COMPETITIVE LANDSCAPE

      • 10.1. Introduction

      • 10.2. Top Winning Strategies

      • 10.3. Product Mapping Of Top 10 Player

      • 10.4. Competitive Dashboard

      • 10.5. Competitive Heatmap

      • 10.6. Top Player Positioning,2022

    • CHAPTER 11: COMPANY PROFILES

      • 11.1. Elekta

        • 11.1.1. Company Overview

        • 11.1.2. Key Executives

        • 11.1.3. Company Snapshot

        • 11.1.4. Operating Business Segments

        • 11.1.5. Product Portfolio

        • 11.1.6. Business Performance

        • 11.1.7. Key Strategic Moves and Developments

      • 11.2. Electronic Registry Systems, Inc.

        • 11.2.1. Company Overview

        • 11.2.2. Key Executives

        • 11.2.3. Company Snapshot

        • 11.2.4. Operating Business Segments

        • 11.2.5. Product Portfolio

        • 11.2.6. Business Performance

        • 11.2.7. Key Strategic Moves and Developments

      • 11.3. Onco, Inc.

        • 11.3.1. Company Overview

        • 11.3.2. Key Executives

        • 11.3.3. Company Snapshot

        • 11.3.4. Operating Business Segments

        • 11.3.5. Product Portfolio

        • 11.3.6. Business Performance

        • 11.3.7. Key Strategic Moves and Developments

      • 11.4. C/Net Solutions

        • 11.4.1. Company Overview

        • 11.4.2. Key Executives

        • 11.4.3. Company Snapshot

        • 11.4.4. Operating Business Segments

        • 11.4.5. Product Portfolio

        • 11.4.6. Business Performance

        • 11.4.7. Key Strategic Moves and Developments

      • 11.5. Rocky Mountain Cancer Data Systems

        • 11.5.1. Company Overview

        • 11.5.2. Key Executives

        • 11.5.3. Company Snapshot

        • 11.5.4. Operating Business Segments

        • 11.5.5. Product Portfolio

        • 11.5.6. Business Performance

        • 11.5.7. Key Strategic Moves and Developments

      • 11.6. McKesson Corporation

        • 11.6.1. Company Overview

        • 11.6.2. Key Executives

        • 11.6.3. Company Snapshot

        • 11.6.4. Operating Business Segments

        • 11.6.5. Product Portfolio

        • 11.6.6. Business Performance

        • 11.6.7. Key Strategic Moves and Developments

      • 11.7. Ordinal Data Inc.

        • 11.7.1. Company Overview

        • 11.7.2. Key Executives

        • 11.7.3. Company Snapshot

        • 11.7.4. Operating Business Segments

        • 11.7.5. Product Portfolio

        • 11.7.6. Business Performance

        • 11.7.7. Key Strategic Moves and Developments

      • 11.8. Conduent Inc

        • 11.8.1. Company Overview

        • 11.8.2. Key Executives

        • 11.8.3. Company Snapshot

        • 11.8.4. Operating Business Segments

        • 11.8.5. Product Portfolio

        • 11.8.6. Business Performance

        • 11.8.7. Key Strategic Moves and Developments

      • 11.9. IBM

        • 11.9.1. Company Overview

        • 11.9.2. Key Executives

        • 11.9.3. Company Snapshot

        • 11.9.4. Operating Business Segments

        • 11.9.5. Product Portfolio

        • 11.9.6. Business Performance

        • 11.9.7. Key Strategic Moves and Developments

      • 11.10. HimagineSolutions Inc.

        • 11.10.1. Company Overview

        • 11.10.2. Key Executives

        • 11.10.3. Company Snapshot

        • 11.10.4. Operating Business Segments

        • 11.10.5. Product Portfolio

        • 11.10.6. Business Performance

        • 11.10.7. Key Strategic Moves and Developments

    • LIST OF TABLES

    • TABLE 1. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 2. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR STANDALONE SOFTWARE, BY REGION, 2022-2032 ($MILLION)
    • TABLE 3. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR INTEGRATED SOFTWARE, BY REGION, 2022-2032 ($MILLION)
    • TABLE 4. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 5. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE, BY REGION, 2022-2032 ($MILLION)
    • TABLE 6. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED, BY REGION, 2022-2032 ($MILLION)
    • TABLE 7. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 8. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY REGION, 2022-2032 ($MILLION)
    • TABLE 9. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY REGION, 2022-2032 ($MILLION)
    • TABLE 10. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY REGION, 2022-2032 ($MILLION)
    • TABLE 11. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH AND CLINICAL STUDIES, BY REGION, 2022-2032 ($MILLION)
    • TABLE 12. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 13. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY REGION, 2022-2032 ($MILLION)
    • TABLE 14. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY REGION, 2022-2032 ($MILLION)
    • TABLE 15. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2022-2032 ($MILLION)
    • TABLE 16. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS ANDTHIRD-PARTY ADMINISTRATORS (TPAS), BY REGION, 2022-2032 ($MILLION)
    • TABLE 17. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS AND MEDICAL PRACTICES, BY REGION, 2022-2032 ($MILLION)
    • TABLE 18. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY REGION, 2022-2032 ($MILLION)
    • TABLE 19. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY REGION, 2022-2032 ($MILLION)
    • TABLE 20. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY REGION, 2022-2032 ($MILLION)
    • TABLE 21. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2022-2032 ($MILLION)
    • TABLE 22. NORTH AMERICA CANCER PATIENT REGISTRY SOFTWARE, BY REGION, 2022-2032 ($MILLION)
    • TABLE 23. NORTH AMERICA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 24. NORTH AMERICA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 25. NORTH AMERICA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 26. NORTH AMERICA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 27. NORTH AMERICA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 28. U.S. CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 29. U.S. CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 30. U.S. CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 31. U.S. CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 32. U.S. CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 33. CANADA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 34. CANADA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 35. CANADA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 36. CANADA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 37. CANADA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 38. MEXICO CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 39. MEXICO CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 40. MEXICO CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 41. MEXICO CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 42. MEXICO CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 43. EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY REGION, 2022-2032 ($MILLION)
    • TABLE 44. EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 45. EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 46. EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 47. EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 48. EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 49. FRANCE CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 50. FRANCE CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 51. FRANCE CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 52. FRANCE CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 53. FRANCE CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 54. GERMANY CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 55. GERMANY CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 56. GERMANY CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 57. GERMANY CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 58. GERMANY CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 59. ITALY CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 60. ITALY CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 61. ITALY CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 62. ITALY CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 63. ITALY CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 64. SPAIN CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 65. SPAIN CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 66. SPAIN CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 67. SPAIN CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 68. SPAIN CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 69. UK CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 70. UK CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 71. UK CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 72. UK CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 73. UK CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 74. RUSSIA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 75. RUSSIA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 76. RUSSIA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 77. RUSSIA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 78. RUSSIA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 79. REST OF EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 80. REST OF EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 81. REST OF EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 82. REST OF EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 83. REST OF EUROPE CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 84. ASIA-PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY REGION, 2022-2032 ($MILLION)
    • TABLE 85. ASIA-PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 86. ASIA-PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 87. ASIA-PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 88. ASIA-PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 89. ASIA-PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 90. CHINA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 91. CHINA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 92. CHINA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 93. CHINA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 94. CHINA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 95. JAPAN CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 96. JAPAN CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 97. JAPAN CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 98. JAPAN CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 99. JAPAN CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 100. INDIA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 101. INDIA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 102. INDIA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 103. INDIA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 104. INDIA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 105. SOUTH KOREA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 106. SOUTH KOREA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 107. SOUTH KOREA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 108. SOUTH KOREA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 109. SOUTH KOREA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 110. AUSTRALIA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 111. AUSTRALIA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 112. AUSTRALIA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 113. AUSTRALIA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 114. AUSTRALIA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 115. THAILAND CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 116. THAILAND CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 117. THAILAND CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 118. THAILAND CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 119. THAILAND CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 120. MALAYSIA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 121. MALAYSIA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 122. MALAYSIA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 123. MALAYSIA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 124. MALAYSIA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 125. INDONESIA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 126. INDONESIA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 127. INDONESIA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 128. INDONESIA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 129. INDONESIA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 130. REST OF ASIA PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 131. REST OF ASIA PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 132. REST OF ASIA PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 133. REST OF ASIA PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 134. REST OF ASIA PACIFIC CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 135. LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY REGION, 2022-2032 ($MILLION)
    • TABLE 136. LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 137. LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 138. LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 139. LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 140. LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 141. BRAZIL CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 142. BRAZIL CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 143. BRAZIL CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 144. BRAZIL CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 145. BRAZIL CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 146. SOUTH AFRICA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 147. SOUTH AFRICA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 148. SOUTH AFRICA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 149. SOUTH AFRICA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 150. SOUTH AFRICA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 151. SAUDI ARABIA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 152. SAUDI ARABIA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 153. SAUDI ARABIA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 154. SAUDI ARABIA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 155. SAUDI ARABIA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 156. UAE CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 157. UAE CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 158. UAE CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 159. UAE CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 160. UAE CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 161. ARGENTINA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 162. ARGENTINA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 163. ARGENTINA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 164. ARGENTINA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 165. ARGENTINA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 166. REST OF LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY TYPE, 2022-2032 ($MILLION)
    • TABLE 167. REST OF LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY DEPLOYMENT MODEL, 2022-2032 ($MILLION)
    • TABLE 168. REST OF LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY FUNCTIONALITY, 2022-2032 ($MILLION)
    • TABLE 169. REST OF LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY DATABASE, 2022-2032 ($MILLION)
    • TABLE 170. REST OF LAMEA CANCER PATIENT REGISTRY SOFTWARE, BY END USER, 2022-2032 ($MILLION)
    • TABLE 171. ELEKTA: KEY EXECUTIVES
    • TABLE 172. ELEKTA: COMPANY SNAPSHOT
    • TABLE 173. ELEKTA: OPERATING SEGMENTS
    • TABLE 174. ELEKTA: PRODUCT PORTFOLIO
    • TABLE 175. ELEKTA: KEY STRATEGIC MOVES AND DEVELOPMENTS
    • TABLE 176. ELECTRONIC REGISTRY SYSTEMS, INC.: KEY EXECUTIVES
    • TABLE 177. ELECTRONIC REGISTRY SYSTEMS, INC.: COMPANY SNAPSHOT
    • TABLE 178. ELECTRONIC REGISTRY SYSTEMS, INC.: OPERATING SEGMENTS
    • TABLE 179. ELECTRONIC REGISTRY SYSTEMS, INC.: PRODUCT PORTFOLIO
    • TABLE 180. ELECTRONIC REGISTRY SYSTEMS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
    • TABLE 181. ONCO, INC.: KEY EXECUTIVES
    • TABLE 182. ONCO, INC.: COMPANY SNAPSHOT
    • TABLE 183. ONCO, INC.: OPERATING SEGMENTS
    • TABLE 184. ONCO, INC.: PRODUCT PORTFOLIO
    • TABLE 185. ONCO, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
    • TABLE 186. C/NET SOLUTIONS: KEY EXECUTIVES
    • TABLE 187. C/NET SOLUTIONS: COMPANY SNAPSHOT
    • TABLE 188. C/NET SOLUTIONS: OPERATING SEGMENTS
    • TABLE 189. C/NET SOLUTIONS: PRODUCT PORTFOLIO
    • TABLE 190. C/NET SOLUTIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS
    • TABLE 191. ROCKY MOUNTAIN CANCER DATA SYSTEMS: KEY EXECUTIVES
    • TABLE 192. ROCKY MOUNTAIN CANCER DATA SYSTEMS: COMPANY SNAPSHOT
    • TABLE 193. ROCKY MOUNTAIN CANCER DATA SYSTEMS: OPERATING SEGMENTS
    • TABLE 194. ROCKY MOUNTAIN CANCER DATA SYSTEMS: PRODUCT PORTFOLIO
    • TABLE 195. ROCKY MOUNTAIN CANCER DATA SYSTEMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
    • TABLE 196. MCKESSON CORPORATION: KEY EXECUTIVES
    • TABLE 197. MCKESSON CORPORATION: COMPANY SNAPSHOT
    • TABLE 198. MCKESSON CORPORATION: OPERATING SEGMENTS
    • TABLE 199. MCKESSON CORPORATION: PRODUCT PORTFOLIO
    • TABLE 200. MCKESSON CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
    • TABLE 201. ORDINAL DATA INC.: KEY EXECUTIVES
    • TABLE 202. ORDINAL DATA INC.: COMPANY SNAPSHOT
    • TABLE 203. ORDINAL DATA INC.: OPERATING SEGMENTS
    • TABLE 204. ORDINAL DATA INC.: PRODUCT PORTFOLIO
    • TABLE 205. ORDINAL DATA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
    • TABLE 206. CONDUENT INC: KEY EXECUTIVES
    • TABLE 207. CONDUENT INC: COMPANY SNAPSHOT
    • TABLE 208. CONDUENT INC: OPERATING SEGMENTS
    • TABLE 209. CONDUENT INC: PRODUCT PORTFOLIO
    • TABLE 210. CONDUENT INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
    • TABLE 211. IBM: KEY EXECUTIVES
    • TABLE 212. IBM: COMPANY SNAPSHOT
    • TABLE 213. IBM: OPERATING SEGMENTS
    • TABLE 214. IBM: PRODUCT PORTFOLIO
    • TABLE 215. IBM: KEY STRATEGIC MOVES AND DEVELOPMENTS
    • TABLE 216. HIMAGINESOLUTIONS INC.: KEY EXECUTIVES
    • TABLE 217. HIMAGINESOLUTIONS INC.: COMPANY SNAPSHOT
    • TABLE 218. HIMAGINESOLUTIONS INC.: OPERATING SEGMENTS
    • TABLE 219. HIMAGINESOLUTIONS INC.: PRODUCT PORTFOLIO
    • TABLE 220. HIMAGINESOLUTIONS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

    • LIST OF FIGURES

    • FIGURE 1. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET SEGMENTATION
    • FIGURE 2. GLOBAL CANCER PATIENT REGISTRY SOFTWARE MARKET
    • FIGURE 3. SEGMENTATION CANCER PATIENT REGISTRY SOFTWARE MARKET
    • FIGURE 4. TOP INVESTMENT POCKET IN CANCER PATIENT REGISTRY SOFTWARE MARKET
    • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
    • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
    • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
    • FIGURE 8. LOW THREAT OF SUBSTITUTION
    • FIGURE 9. HIGH COMPETITIVE RIVALRY
    • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCANCER PATIENT REGISTRY SOFTWARE MARKET
    • FIGURE 11. CANCER PATIENT REGISTRY SOFTWARE MARKET SEGMENTATION, BY BY TYPE
    • FIGURE 12. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR STANDALONE SOFTWARE, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 13. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR INTEGRATED SOFTWARE, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 14. CANCER PATIENT REGISTRY SOFTWARE MARKET SEGMENTATION, BY BY DEPLOYMENT MODEL
    • FIGURE 15. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 16. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 17. CANCER PATIENT REGISTRY SOFTWARE MARKET SEGMENTATION, BY BY FUNCTIONALITY
    • FIGURE 18. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 19. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 20. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 21. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH AND CLINICAL STUDIES, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 22. CANCER PATIENT REGISTRY SOFTWARE MARKET SEGMENTATION, BY BY DATABASE
    • FIGURE 23. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 24. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 25. CANCER PATIENT REGISTRY SOFTWARE MARKET SEGMENTATION, BY BY END USER
    • FIGURE 26. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS ANDTHIRD-PARTY ADMINISTRATORS (TPAS), BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 27. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS AND MEDICAL PRACTICES, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 28. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 29. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 30. CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
    • FIGURE 31. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
    • FIGURE 32. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
    • FIGURE 33. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
    • FIGURE 34. PRODUCT MAPPING OF TOP 10 PLAYERS
    • FIGURE 35. COMPETITIVE DASHBOARD
    • FIGURE 36. COMPETITIVE HEATMAP: CANCER PATIENT REGISTRY SOFTWARE MARKET
    • FIGURE 37. Top player positioning, 2022
    • FIGURE 38. ELEKTA: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 39. ELEKTA: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 40. ELEKTA: REVENUE SHARE, BY REGION, 2032 (%)
    • FIGURE 41. ELECTRONIC REGISTRY SYSTEMS, INC.: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 42. ELECTRONIC REGISTRY SYSTEMS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 43. ELECTRONIC REGISTRY SYSTEMS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
    • FIGURE 44. ONCO, INC.: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 45. ONCO, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 46. ONCO, INC.: REVENUE SHARE, BY REGION, 2032 (%)
    • FIGURE 47. C/NET SOLUTIONS: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 48. C/NET SOLUTIONS: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 49. C/NET SOLUTIONS: REVENUE SHARE, BY REGION, 2032 (%)
    • FIGURE 50. ROCKY MOUNTAIN CANCER DATA SYSTEMS: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 51. ROCKY MOUNTAIN CANCER DATA SYSTEMS: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 52. ROCKY MOUNTAIN CANCER DATA SYSTEMS: REVENUE SHARE, BY REGION, 2032 (%)
    • FIGURE 53. MCKESSON CORPORATION: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 54. MCKESSON CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 55. MCKESSON CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
    • FIGURE 56. ORDINAL DATA INC.: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 57. ORDINAL DATA INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 58. ORDINAL DATA INC.: REVENUE SHARE, BY REGION, 2032 (%)
    • FIGURE 59. CONDUENT INC: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 60. CONDUENT INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 61. CONDUENT INC: REVENUE SHARE, BY REGION, 2032 (%)
    • FIGURE 62. IBM: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 63. IBM: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 64. IBM: REVENUE SHARE, BY REGION, 2032 (%)
    • FIGURE 65. HIMAGINESOLUTIONS INC.: NET SALES, 2020-2022 ($MILLION)
    • FIGURE 66. HIMAGINESOLUTIONS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
    • FIGURE 67. HIMAGINESOLUTIONS INC.: REVENUE SHARE, BY REGION, 2032 (%)

     
     
    With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

    We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

    • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
    • Technologically sophisticated and reliable insights through well audited and veracious research methodology
    • Sovereign research proceeds that present a tangible depiction of marketplace


    With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

    Secondary research
    We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

    • Patent and regulatory databases for understanding of technical & legal developments
    • Scientific and technical writings for product information and related preemptions
    • Regional government and statistical databases for macro analysis
    • Authentic new articles, web-casts and other related releases for market evaluation
    • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


    Primary research
    Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

    • Validates and improves the data quality and strengthens research proceeds
    • Further develops analyst team’s market understanding and expertise
    • Supplies authentic information about market size, share, growth and forecasts


    Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

    • Chief executives and VPs of leading corporations specific to industry
    • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


    Analyst tools and models
    AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

    PURCHASE OPTIONS

    Call or Email us

    U.S.-Canada Toll-free: +1-800-792-5285
    Int'l : +1-503-894-6022
    Europe : +44-845-528-1300
    Email : help@alliedmarketresearch.com

    Looking for Customization?

     Customization Request

    Have a Question?

     Speak with Analyst

    Any Confusion?

     Inquire Before Buying

    Have a glance of the Report

      Enquiry Now
    RELATED TAGS

    Purchase Full Report of
    Cancer Patient Registry Software Market

    Start reading.
    This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

    • Online Only
    • $3,690
    • Online cloud access only
    • Restricted print, copy, paste & download
    • Read only
    • Free industry update
      (Within 180 days)
    • Free report update in next update cycle
    • Data Pack
    • $3,840
    • Restricted to one authorized user
    • One print only
    • Available in
      Excel
    • Free industry update
      (Within 180 days)
    •   Free report update in next update cycle
    • Single User
    • $5,820
    • Restricted to one authorized user
    • One print only
    • Available in
      PDF
    • Free industry update
      (Within 180 days)
    •   Free report update in next update cycle
    • Five Users
    • $6,540
    • Limited to five authorized users
    • Print upto five copies
    • Available in
      PDF
    • Free industry update
      (Within 180 days)
    •   Free report update in next update cycle

    • Enterprise
      License/PDF

    • $9,870
    • Unlimited
      within
      company/enterprise
    • Available in Excel & PDF
    • Free industry update
      (Within 180 days)
    •   Free report update in next update cycle

    • Library
      Membership

    • $999 $ 1,175
      Per User/ Per month/ Billed annually
    • Published Content
      E-access
    • Company Profiles
      E-access
    • Newly Added Content Access
    • 10 PDF
      Downloads
    • 5 Excel Data
      Pack Downloads
    • 250 Company Profiles PDF Downloads
    • Buy Now

    *Taxes/Fees, if applicable will be added during checkout. All prices in USD

    RELATED REPORTS
     

    Why Allied Market Research?

     

    Infallible Methodology

    To ensure high-level data integrity, accurate analysis, and impeccable forecasts

    Analyst Support

    For complete satisfaction

    Customization

    On-demand customization of scope of the report to exactly meet your needs

    TARGETED MARKET VIEW

    Targeted market view to provide pertinent information and save time of readers

    Get fresh content delivered

    Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

    Get Industry Data Alerts

    Why Allied Market Research?

    Infallible Methodology

    To ensure high-level data integrity, accurate analysis, and impeccable forecasts

    Analyst Support

    For complete satisfaction

    Customization

    On-demand customization of scope of the report to exactly meet your needs

    TARGETED MARKET VIEW

    Targeted market view to provide pertinent information and save time of readers